Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.810
+0.020 (1.12%)
At close: Mar 28, 2025, 4:00 PM
1.821
+0.011 (0.60%)
After-hours: Mar 28, 2025, 7:53 PM EDT
Zentalis Pharmaceuticals Revenue
In the year 2024, Zentalis Pharmaceuticals had annual revenue of $67.43M. Zentalis Pharmaceuticals had revenue of $26.87M in the quarter ending December 31, 2024.
Revenue (ttm)
$67.43M
Revenue Growth
n/a
P/S Ratio
1.91
Revenue / Employee
$406,175
Employees
166
Market Cap
129.98M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ZNTL News
- 4 days ago - Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - GlobeNewsWire
- 5 days ago - Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 15 days ago - Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - GlobeNewsWire
- 27 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer - GlobeNewsWire